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Available online 3 March 2016The humanNTERA2/D1 (NT2) cells generate postmitotic neurons (NT2N cells) upon retinoic acid (RA) treatment
and are functionally integrated in the host tissue following grafting into the rodent and human brain, thus
representing a promising source for neuronal replacement therapy. Yet the major limitations of this model are
the lengthy differentiation procedure and its low efﬁciency, although recent studies suggest that the differentia-
tion process can be shortened to less than 1 week using nucleoside analogues. To explore whether short-term
exposure of NT2 cells to the nucleoside analogue cytosine β-D-arabinofuranoside (AraC) could be a suitable
method to efﬁciently generate mature neurons, we conducted a neurochemical andmorphometric characteriza-
tion of AraC-differentiated NT2N (AraC/NT2N) neurons and improved the differentiation efﬁciency bymodifying
the cell culture schedule. Moreover, we analyzed the neurotransmitter phenotypes of AraC/NT2N neurons. Cul-
tures obtained by treatment with AraCwere highly enriched in postmitotic neurons and essentially composed of
dual glutamatergic/cholinergic neurons, which contrasts with the preferential GABAergic phenotype that we
found after RA differentiation.
Taken together, our results further reinforce the notion NT2 cells are a versatile source of neuronal phenotypes
and provide a new encouraging platform for studying mechanisms of neuronal differentiation and for exploring
neuronal replacement strategies.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The pluripotent NTERA2/D1 (NT2) cell line, derived from human
testicular embryonic carcinoma cells (Andrews, 1984), represents a
committed neuronal precursor cell that can be induced to differentiate
in vitro into postmitotic cells, known as NT2N (or hNT) neurons. More-
over, NT2N cells have the ability to establish functional synapses and to
develop neuronal electrophysiological properties, including generationt of Neurosciences, Faculty of
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. This is an open access article underof action potentials and the presence of spontaneous excitatory and in-
hibitory postsynaptic currents (Hartley et al., 1999a; Podrygajlo et al.,
2010; Öz et al., 2013). Consequently, the NT2N cell type is now widely
accepted as a suitablemodel for the study of neuronal networks and dif-
ferentiation and synaptogenesis processes.
In addition, theNT2 clonal line represents a promising cell source for
neuronal replacement therapy applicable to the treatment of someneu-
rological conditions, including neurodegenerative disorders such as
Parkinson's, Huntington's, and Alzheimer's diseases and acute brain in-
jury such as stroke and head trauma. To this end, grafts or cells in sus-
pension from embryonic ventral mesencephalic tissue, adrenal
medullary cells, other neuronal and non-neuronal cells, and even genet-
ically modiﬁed cells have produced encouraging results, but none of
them are fully satisfactory (Martínez-Morales et al., 2013). As a conse-
quence, researchers have focused their efforts on either trying to in-
crease the efﬁcacy of existing tissue and cell candidates or searching
for alternative sources of donor cells. In this sense, NT2N neuronsmain-
tain their neuronal phenotype after transplantation into the rodent
brain (Trojanowski et al., 1993; Kleppner et al., 1995; Baker andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Furthermore, NT2N grafts have been shown to improve motor deﬁcits
in animal models of stroke (Borlongan et al., 1998a,b; Saporta et al.,
1999) and Huntington's disease (Hurlbert et al., 1999), making NT2N
neurons excellent candidates for cell replacement therapy in neurolog-
ical disorders (Trojanowski et al., 1997; Lee et al., 2000; Nelson et al.,
2002; Borlongan et al., 2006; Hara et al., 2008). Indeed, in a phase I clin-
ical trial on 12 patients with basal ganglia stroke and stable motor deﬁ-
cits, NT2N cells were seen to integratewith the host brain tissue for long
periods and with no detectable tumor formation (Kondziolka et al.,
2000; Meltzer et al., 2001; Nelson et al., 2002), leading to a Phase II
study in 18 patients with basal ganglia infarct (Kondziolka et al.,
2005). Although statistical signiﬁcance could not be reached due to
the small population size analyzed, both studies showed an apparent
trend towards functional improvement (Banerjee et al., 2010, for
review).
Progress in the ﬁeld of neuronal replacement using NT2 committed
to differentiate with retinoic acid (RA) is limited by the long time
frame necessary to generate postmitotic NT2N neurons and also by
the low proportion of terminally differentiated neurons. Thus, neuronal
differentiation of NT2 progenitors, ﬁrst described by Andrews (1984)
and later on improved by Pleasure et al. (1992), involves treatment of
NT2 progenitors with RA during 4 weeks followed by mitotic inhibitors
for 7–10 days, with only about 5% of the initial population of NT2 cells
becoming differentiated. Recently, using nucleoside analogues, Musch
et al. (2010) achieved successful differentiation of NT2 cells in less
than 1 week, thus offering a rapid protocol to obtain postmitotic neu-
rons, which could be potentially useful for neuronal replacement thera-
py. However, whereas NT2N neurons obtained by treatment with RA
have been shown to express a variety of classical neurotransmitters,
neurotransmitter-related enzymes and transporters (Podrygajlo et al.,
2009; Coyle et al., 2011), there are no published data about neuronal
phenotypes resulting from nucleoside-induced differentiation of NT2
cells.
In this study, using neuron-speciﬁc and neurotransmitter pheno-
type markers, high-resolution ﬂuorescencemicroscopy, and western
blot analysis, we demonstrate that NT2 progenitors can be commit-
ted to differentiate into NT2N neurons with high efﬁciency by
short-term (6 days) exposure to the nucleoside analogue cytosine
β-D-arabinofuranoside (AraC). AraC-differentiated neurons are irre-
versibly postmitotic, express late neuronal markers, aremorphomet-
rically identiﬁable and display a dual glutamatergic/cholinergic
neurotransmitter phenotype, which differs from that observed in
RA-differentiated NT2N neurons. Our data, further conﬁrm that
NT2 progenitors constitute a versatile source of neurons with a po-
tential use in cell-replacement therapy for multiple degenerative
disorders.
2. Materials and methods
2.1. Cell culture and differentiation
Human teratocarcinoma NTERA2-D1 (hereafter referred to as NT2)
cells from the American Type Culture Collection (ATCC®, CRL-1973™)
were maintained in complete medium (Dulbecco's Modiﬁed Eagle me-
dium (DMEM®), ATCC 30-2002™- supplementedwith 10% fetal bovine
serum (FBS), Sigma-Aldrich, St Louis, MO, USA; and antibiotics, 100 U/
mL penicillin and 100 μg/mL streptomycin, Gibco, Life Technologies
S.A., Madrid, Spain) at 37 °C under a humidiﬁed atmosphere containing
5% CO2. For differentiation of NT2 progenitors with all-trans retinoic
acid (RA, Sigma-Aldrich), cells were treated as previously described by
Pleasure et al. (1992), thus obtaining RA-differentiated NT2N cells,
which will be referred to as RA/NT2N cells in this paper (see supple-
mentary material and methods for details).
The induction of neuronal differentiation using 2′-deoxy-5-
azacytidine (DAC) or cytosine β-D-arabinofuranoside (AraC) wasperformed based on a previous report showing that exposure of
NT2 cells for only 6 days leads to neuronal differentiation (Musch
et al., 2010). For preliminary assays, progenitor NT2 cells were ex-
posed to equitoxic concentrations of DAC or AraC (Tan et al., 2007;
Musch et al., 2010). Brieﬂy, NT2 cells at 80–90% conﬂuence were
treated with 1 μM DAC or 20 μM AraC-containing medium for 24 h,
48 h, 72 h, or 6 days. Medium from cultures treated for more than
48 h was replaced with fresh complete medium supplemented
with the corresponding nucleoside analogue every 2 days. Results
of preliminary experiments led us to choose AraC to induce neuronal
differentiation (see results below), and therefore, this compound
was used for subsequent experiments. Because low cell density can
compromise neuronal survival and differentiation, we tested wheth-
er increased conﬂuence improves the yield of terminally AraC-
differentiated neurons (hereafter referred to as AraC/NT2N cells).
The protocol used for this purpose is described in detail in supple-
mentary material and methods.
2.2. Western blot
Cell pellets were collected by centrifugation at different times of
differentiation treatment as indicated for each experiment and
lysed in homogenization buffer (10 mM Tris–HCl buffer, pH 7.4,
2 mM MgCl2, and 0.32 M sucrose) containing protease inhibitors
(0.5 mM iodoacetamide and 1 mM phenylmethylsulfonyl ﬂuoride,
PMSF). Depending on the antigen to be analyzed, different amounts
of denatured lysates (5–30 μg) were loaded, resolved by SDS–poly-
acrylamide (SDS–PAGE) gels and transferred to polyvinylidene ﬂuo-
ridemembranes (Bio-Rad, Madrid, Spain), and speciﬁc protein bands
were detected using conventional immunoblot protocols. Primary
and secondary antibodies are described in Table 1 and Table S1, re-
spectively (further information about immunoblot analysis is pro-
vided as supplementary material).
2.3. Immunoﬂuorescence
Cells were ﬁxed in buffered 4% paraformaldehyde for 4 min, both
at 20°–25 °C. After blocking for 1 h with gelatin-histology buffer
(0.1 M PBS, pH 7.4, containing 0.22% gelatin (Panreac, Barcelona,
Spain), 0.05% saponin (Sigma-Aldrich), and 1% serum albumin bo-
vine (BSA, Sigma-Aldrich), cells were incubated with primary anti-
bodies (Table 1, for details) at 4 °C overnight. Then, the appropriate
ﬂuorescent dye-conjugated secondary antibodies (Table S1 for de-
tails) were applied and nuclei were counterstained with Hoechst
33,342 (Sigma-Aldrich, diluted to 0.1 μg/mL in gelatin histology buff-
er) (see supplementary material and methods for further details).
2.4. BrdU labeling
Undifferentiated NT2 progenitors and AraC-treated NT2 cultures
were labeled with 10 μM 5-bromo-2′-deoxyuridine (BrdU;
ThermoFisher Scientiﬁc, Barcelona, Spain) at various times after ini-
tiation of AraC treatment (0, 2, 4, 8, 20 and 68 h) and ﬁxed for immu-
noﬂuorescence labeling 4 h later. Additionally, to test whether
differentiated AraC/NT2N neurons were irreversibly postmitotic,
after the 6-day differentiation process, AraC-containing medium
was replaced with AraC-free complete medium, and cells were treat-
ed with BrdU for either 4 or 24 h and analyzed at survival times of 7,
9, and 11 days. Antigen retrieval for BrdU staining was performed as
described by Solovei et al. (2006). Brieﬂy, coverslips containing the
paraformaldehyde-ﬁxed cells were treated with PBS (0.1 M,
pH 7.4) containing 0.1% (v/v) TX-100 (PBS-T), treated with HCl
0.1 M for 10 min, and then equilibrated in Saline Sodium Citrate
(SSC; 0.15 M NaCl, 0.015 M sodium citrate) at room temperature
(21–23 °C). Thereafter, cells were incubated in 50% formamide in
SSC during 15 min at room temperature, followed by treatment
Table 1
Primary antibodies used in this study.
Antibody Dilution Clonality Species and isotype Immunizing antigen Source, catalog no.
IF WB
NeuN 1:200 1:1000 Monoclonal Mouse IgG1 Puriﬁed cell nuclei from mouse brain. Millipore, MAB377, clone A60.
Nav1.6 Nav channel 1:200 Monoclonal Mouse IgG1
Synthetic peptide corresponding to amino acids
459–476 of the intracellular loop I-II of rat Nav1.6.
NeuroMab, 75–026, clone K87A/10.
β-III tubulin 1:1000 1:1000 Polyclonal
Afﬁnity-puriﬁed chicken
serum
Synthetic peptides corresponding to different
regions shared by human and rat β-tubulin III.
Abcam, ab41489.
NF200 1:400 1:10,000 Polyclonal
Rabbit IgGs,
afﬁnity-puriﬁed
200 kDa neuroﬁlament, puriﬁed from bovine
spinal cord.
Sigma-Aldrich, N4142.
DCX 1:200 1:500 Polyclonal Goat IgGs, afﬁnity-puriﬁed
Synthetic peptide mapping at the C-terminus of
human doublecortin.
Santa Cruz Biotech. Inc., sc-8066.
MAP2 1:200 Monoclonal Mouse IgG1
Bovine MAP2. Recognizes the high molecular
weight forms of MAP2, MAP2a and MAP2b.
Sigma-Aldrich, M2320, clone AP-20.
BrDU 1:250 Monoclonal Mouse IgG2a 5-Iodouridine covalently coupled to ovalbumin.
ThermoFisher Scientiﬁc, MA3-071,
clone BU-1.
GAD67 1:100 1:1000 Monoclonal Mouse IgG2a Recombinant GAD67 protein of human origin. Millipore, MAB5406, clone 1G10.2.
ChAT 1:100 1:1000 Polyclonal
Goat serum, afﬁnity
puriﬁed
Human placental enzyme. Millipore, AB144P.
TH 1:100 1:1000 Polyclonal
Rabbit serum, afﬁnity
puriﬁed
Denatured tyrosine hydroxylase from rat
pheochromocytoma.
Millipore, AB152.
VGluT1 1:200 1:1500 Polyclonal
Rabbit IgGs,
afﬁnity-puriﬁed
Synthetic peptide from a cytoplasmic loop of rat
(C-terminal) VGluT1.
Abcam, ab72311.
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ing plates were placed on ice and cells were washed three times with
cold PBS-T and processed for double β-III tubulin and BrdU immuno-
ﬂuorescence as described above.
2.5. Microscope studies and imaging
All microscope images were acquired with an epiﬂuorescence mi-
croscope Carl Zeiss Axio Observer.Z1, equipped with an HXP120C
metal halide lamp illumination source and a high-resolutionmonochro-
matic camera (AxioCam MRm, 1388 × 1040 pixels), all from Carl Zeiss
MicroImaging, Inc. (Gottigen, Germany).
Conventional epiﬂuorescence images (Figs. 5 and 6) were acquired
using a 20× Plan-Apochromat objective (NA 0.8). Higher-resolution im-
ages (Figs. 2, 4, and 6 and Figs. S3–S5) were acquired using a structured
illumination module (ApoTome) and a XYZ motorized stage (Carl Zeiss
MicroImaging, Inc), using a 63× Plan-Apochromat objective (NA 1.4),
and optical sections (0.24 μm intervals in the z-axis) were obtained
with the Zeiss ApoTome device, with camera settings adjusted to obtain
images with a pixel size of 0.01 μm2.
2.6. BrdU-positive cell counts
Conventional epiﬂuorescence images 447.63× 335.40 μmof cells co-
immunostained forβ-III tubulin and BrdU, and counterstained for nuclei
with Hoechst 33,342, were acquired using a 20× Plan-Apochromat ob-
jective. All images from each independent experiment were acquired
with identical exposure and lighting conditions, and nuclei displaying
BrdU staining above a set threshold level (by NIH ImageJ software)
were scored as positive. Three independent experiments were per-
formed, each with two coverslips per experimental condition. Quantiﬁ-
cations were performed on 5–7 images per slide (10–14 per
experimental condition), and the percentage of BrdU-positive cells
was calculated.
2.7. Statistical analysis
Results were statistically analyzed in GraphPad Prism (version 5.0,
GraphPad Software Inc., San Diego, CA) and presented as mean ±
SEM. Two-tailed unpaired t-test or one-way analysis of variance
(ANOVA) followed by Bonferroni post hoc test were used. p b 0.05was considered signiﬁcant. Average values were obtained from either
3 or 4 independent experiments.
3. Results
3.1. Short exposure of NT2 progenitors to AraC efﬁciently promotes acquisi-
tion of neuron-like morphology.
First, we reproduced the RA-induced differentiation protocol previ-
ously described by Pleasure et al. (1992) and showed that only 4.4 ±
0.8% (SEM) of the initial population become terminally differentiated
into RA/NT2N neurons, in line with the observations by Pleasure et al.
(1992). Subsequently, we tested the ability of DAC and AraC to promote
short-term neuron-like differentiation, showing that treatment with
AraC (but not DAC) for only 6 days led to differentiation of NT2 progen-
itors into highly polarized cells with long processes, indicative of their
neuronal identity. Results of these preliminary experiments are de-
scribed in detail in supplementary results and illustrated in supplemen-
tary Figs. S1 and S2.
However, despite the apparent efﬁcacy of AraC to promote neuronal
differentiation, after the 6-day period of treatment, cultures were ex-
tremely sparse. Indeed, only 42.18 ± 2.78% and 9.3 ± 1.1% of the initial
cell population had survived after 72 h and 6 days of treatment, respec-
tively. Therefore, we tested whether survival could be improved by in-
creasing cell conﬂuence. For this purpose, after 72 h of AraC
treatment, cells were harvested, replated at higher density, and treated
with AraC for 3 additional days. In fact, this procedure resulted in a 2-
fold increase of surviving cells (20.2 ± 3.3% vs. 9.3 ± 1.1%). Fig. 1 illus-
trates morphological changes occurring during the ﬁrst 72 h of AraC-
induced differentiation (Figs. 1A–D) and the features of the culture at
the end of the standard (Fig. 1E) and modiﬁed schedules (Fig. 1F). As
it can be observed, both procedures yielded a culture highly enriched
in cells with neuronal morphology (AraC/NT2N cells).
3.2. Treatment of NT2 cells with AraC for 6 days induces terminal neuron
differentiation with high efﬁciency.
To ascertain whether AraC/NT2N cells expressedmarkers consistent
with a neuronal phenotype, we analyzed the expression of the neuron-
speciﬁc cytoskeletal proteins neuroﬁlament 200 kDa (NF200), β-III tu-
bulin, and doublecortin (DCX) during the time course of RA- and
AraC-induced differentiation process, by immunoblot of whole cell
Fig. 1. Phase-contrast micrographs illustrating the time course of AraC-induced differentiation (A–E) and the effects of increasing cell conﬂuence at 72 h of AraC treatment in the state of
cultures after 6-day period of treatment (F). Asterisks indicate the presence of a population of ﬂat cells with phase-translucent cytoplasm and non-neuronal morphology at the end of
treatment. Scale bar = 50 μm (applies to A–F).
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expression, reaching a maximum at the end of the differentiation pro-
cess, showing only subtle differences in the relative expression level
during the time course of treatments. By contrast, the temporal expres-
sion proﬁle of β-III tubulin and DCX showed marked differences be-
tween the RA and the AraC induction of differentiation. Thus, upon RA
treatment of NT2 progenitors, the expression of β-III tubulin increased
rapidly and then decreased, whereas it increased sharply at the end of
the AraC treatment. DCX, in its turn, increased progressively in RA-
treated cells, whereas it showed an up- and downregulation pattern in
AraC-treated cells (Fig. 2A).
Subsequently, we performed immunolabeling experiments for
β-III tubulin, NF200 and DCX in NT2 progenitors, RA/NT2N and
AraC/NT2N cells (Figs. 2B–J). No or barely detectable NF200
immunolabeling was observed in NT2 cells (Fig. 2B), whereas a
bright signal could be observed in both RA/NT2N (Fig. 2E) and
AraC/NT2N (Fig. 2H) cells. Also in good agreement with immuno-
blot results (Fig. 2A), β-III tubulin immunolabeling was diffusely
distributed in the cytoplasm of NT2 progenitors (Fig. 2C), whereas
intense immunoreactivity was found in varicosities within theneurites of RA/NT2N cells (Fig. 2F) and throughout the cell body
and neurites or AraC/NT2N cells (Fig. 2I). NT2 cells resulted dif-
fusely stained by anti-DCX antibody, whereas it gave a strong ﬂuo-
rescent signal in neurites of RA/NT2N cells (Fig. 2G) and
consistently delineated neurites of AraC/NT2N cells (Fig. 2J).
The neuronal identity of AraC/NT2N cells was validated by double
immunoﬂuorescence labeling for NeuN/Fox-3 (a marker of adult
neurons) and β-III tubulin, in cell cultures treated with AraC for
6 days and subjected or not to replating on day 3. Results showed
that AraC/NT2N cells co-express both markers (Figs. S3A–G), along
with MAP2 and the voltage-dependent sodium channel 1.6 (Nav
1.6) (Fig. S4).
Because cultures of NT2 cells treated for 6 days with AraC still
contained a population of presumably non-neuronal cells, NeuN/
Fox-3 staining, together with morphological features, was used to
evaluate the efﬁciency of both schedules to induce neuronal differ-
entiation. For this purpose, we performed cell counts on cell cultures
doubly immunolabeled for NeuN/Fox-3 and β-III tubulin, and cells
negative for NeuN/Fox-3 and those displaying round shapes with
no or short processes were considered to be non-neuronal. Using
Fig. 2. (A) Results of immunoblots and semiquantitative densitometric analysis of immunoreactivity for neuronal markers NF200, β-III tubulin, and DCX during RA- and AraC-induced
differentiation. Immunoblots were performed in whole homogenates of cells harvested at different time points of differentiation using RA (NT2 progenitors, 48 h, 7 days, 14 days, and
28 days and terminally differentiated RA/NT2N neurons) and AraC (NT2 progenitors, 24 h, 48 h, and 72 h and terminally differentiated AraC/NT2N neurons). The amount of protein
loaded per lane was 5 μg for immunoblots against NF200 and β-III tubulin and 20 μg for immunoblots against DCX. The y-axis of graphs show percent optical density of each band nor-
malized to the highest value found during the time course of differentiation. Error bars indicate SEM (n= 4). B. Micrographs of NT2 cells (B–D) and terminally differentiated RA/NT2N
(E–G) and AraC/NT2N (H–J) neurons immunolabeled (green) for NF200 (B, E, H), β-III tubulin (C, F, I) and DCX (D, G, J) combined with chromatin staining using the Hoechst's dye
(pseudocolored red). Micrographs are maximum intensity projections of 4 consecutive optical sections separated by 0.24 μm, obtained using the structured illumination module
(ApoTome) of a ﬂuorescence microscope (Carl Zeiss Axio Observer) equipped with a XYZ motorized stage. Scale bar = 20 μm (applies to B–J).
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interrupted 6-day treatment and 71.3 ± 3.9% of cells subjected to
replating on day 3 fulﬁlled criteria to be considered as AraC/NT2N
neurons. Using these values and the percentage of surviving cellsfollowing 6 days of treatment with AraC (see above), we could con-
clude that 5.14 ± 0.6% and 14.4 ± 2.3% of the initial population of
NT2 progenitors became terminally differentiated AraC/NT2N neu-
rons (Fig. S3H).
Fig. 3. Bar graphs showing results ofmorphometric analyses to compare non-neuronal and AraC/NT2N cells grown in identical conditions. All data represent average values obtained from
99 cells in 3 independent experiments. Data are mean ± SEM. Two-tailed unpaired t-test (***p b 0.0001).
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AraC to promote neuronal differentiation of NT2 cells in a short
time period and highlight the importance of optimizing culture
conditions.
3.3. Cells identiﬁed as AraC/NT2N neurons are morphometrically distin-
guishable from non-neuronal cells
To assess whether phenotypes classiﬁed as neuronal and non-
neuronal after AraC-induced differentiation were morphometrically
distinguishable, we analyzed the average nuclear and whole cell area
of both cell populations, classiﬁed on the basis of NeuN/Fox-3 expres-
sion and morphological features (González-Burguera et al., in press for
details). The average nuclear area of cells classiﬁed as non-neuronal,
was considerably larger (851.53 ± 27.63 μm2) than nuclear area of
AraC/NT2N neurons (339.67 ± 11.91 μm2), whereas no differences in
total cell area were observed (3122.36 ± 95.06 and 3326.82 ±
177.68 μm2, respectively). Consequently, the ratio of nuclear area to
total cell body area was about 2-fold higher in non-neuronal cells
(0.280 ± 0.007) than in AraC/NT2N cells (0.128 ± 0.008) (Fig. 3).
These results clearly reinforce the reliability of criteria used to classify
cell phenotypes resulting from exposure of NT2 progenitors to AraC
treatment.
The average nuclear and soma area, as well as the length and num-
ber of neurites of AraC/NT2N and RA/NT2N neurons wereFig. 4. (A)Western blot analysis of neurotransmitter phenotypemarkers in total cell lysates from
(4 μg) and human U87 glioma cell line lysates (20 μg) were used as positive and negative contr
acetyl transferase (ChAT), glutamate decarboxylase 67 kDa (GAD67), and tyrosine hydroxyla
phenotype markers. (B–M) Immunolabeling (green) against VGluT1 (A–E), ChAT (F–I), and G
NT2 cells, cells treated for 72 h with AraC, and AraC/NT2N and RA/NT2N neurons. Microgra
0.24 μm, obtained by structured illumination microscopy (ApoTome). Scale bar = 20 μm (appmorphometrically analyzed and compared (González-Burguera et al.,
in press, for details). Comparison of the nuclear area between neurons
committed to differentiate with either RA or AraC showed that nuclei
of AraC/NT2N neurons (339.78 ± 12.03 μm2) were 3.2-fold larger
than those of RA/NT2Nneurons (106.83±12.03 μm2). Similarly, the av-
erage soma area of AraC/NT2N neurons (1103.15 ± 41.69 μm2) was
about 4.6-fold larger compared to that of RA/NT2N neurons
(240.17 ± 9.93 μm2). Consequently, the ratio of nuclear to body area
tended to equalize in both phenotypes, although it was signiﬁcantly
lower in AraC/NT2N (0.344 ± 0.017) than in RA/NT2N (0.483 ±
0.015) neurons. Neurites of AraC/NT2N neurons were 105.33 ±
3.55 μm long in average, which represents about half the value found
in RA/NT2N neurons (225.46± 10.94 μm). This, together with a slightly
lower, non-signiﬁcant, number of neurites per cell in AraC/NT2N
(1.85± 0.10) than in RA/NT2 neurons (2.12± 0.13), makes total arbor-
ization 2.2-fold longer in RA/NT2N (390.70 ± 17.89 μm) than in AraC/
NT2N (180.14 ± 9.22 μm). These data showing comparisons between
the morphometric parameters measured in AraC/NT2N and RA/NT2N
cells are presented in González-Burguera et al. (in press); Fig. 1K).
3.4. AraC/NT2N co-express glutamatergic and cholinergic phenotypic
markers
The expression of speciﬁc markers for glutamatergic, cholinergic,
GABAergic, and dopaminergic neurotransmitter phenotypes was ﬁrstNT2 cells (20 μg) during theRA- andAraC-induced differentiation. Rat brain homogenates
ols, respectively. Speciﬁc antibodies to vesicular glutamate transporter 1 (VGluT1), choline
se (TH) enzymes were used as glutamatergic, cholinergic, GABAergic, and dopaminergic
AD67 (J–M) combined with Hoechst's chromatin staining (pseudocolored red) in ﬁxed
phs are maximum intensity projections of 3 consecutive optical sections separated by
lies to B-M).
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this purpose, we used speciﬁc antibodies to vesicular glutamate trans-
porter 1 (VGluT1), choline acetyl transferase (ChAT), and glutamate de-
carboxylase 67 kDa (GAD67) and tyrosine hydroxylase (TH) enzymes.
In rat brain homogenates, used as positive controls, all four antibodies
produced immunoreactive bands (Fig. 4A), consistentwith the size pre-
dicted from the corresponding rat protein sequences. Results obtained
in cell homogenates revealed marked differences between AraC- and
RA-treated cells. Brieﬂy, high VGluT1 and ChAT immunoreactivity was
observed in AraC-differentiated NT2N cells, whereas strong GAD67-
and barely detectable VGluT1 immunoreactivity was detected in RA-
differentiated NT2N cells. We found no TH immunoreactivity in any of
the cell samples analyzed even after overexposure of western blots
(Fig. 4A) (see supplementary results for a detailed description of west-
ern blot results and related discussion).
In agreement with the results of western blot analysis, NT2 progen-
itors exhibited barely detectable VGluT1 immunoﬂuorescence (Fig. 4B),
whereas bright stainingwas detected throughout cells processes of cells
differentiated into neurons by AraC treatment for 72 h and 6 days
(Figs. 4C and D). In the same immunocytochemical staining conditions,
VGluT1-signal was seen as bright foci restricted to varicosities on a
small subset of neurites of RA/NT2N cells (Fig. 4E). ChAT immunoreac-
tivity was diffusely distributed throughout the cytoplasm of NT2 pro-
genitors (Fig. 4F) and extended to neurites of AraC-differentiated cells
(Figs. 4G–H), but no signal above the background level was detected
in RA/NT2N neurons (Fig. 4I). NT2 progenitors (Fig. 4J), and AraC-
treated cells (Figs. 4K–L) were nearly devoid of GAD67 immunoﬂuores-
cence staining, whereas most neurites of RA/NT2N cell displayed bright
staining (Fig. 4M). Immunoﬂuorescence staining showed that virtuallyFig. 5. Epiﬂuorescence microscopy images of AraC/NT2N cells processed for double immunoﬂu
Panoramic view corresponding to a mosaic from multiple images captured with a 20× obje
(B) and ChAT immunoﬂuorescence (C) distribution in an AraC/NT2N neuron (arrowhead) andall AraC/NT2N neurons were both VGluT1- and ChAT-immunopositive,
strongly indicating that these cells co-express glutamatergic and cholin-
ergic markers. Thus, we carried out double VGluT1/ChAT immunoﬂuo-
rescence staining, showing that every VGluT1-positive neuron also
expressed ChAT (Fig. 5A). Although both markers were distributed in
neurites of AraC/NT2N cells, VGluT1 immunoﬂuorescence was highly
polarized to neurites, whereas anti-ChAT antibody also stained ﬂat
lamellipodia (Figs. 5B–D). Because cells committed to differentiate
into neurons by AraC treatment cannot be physically separated from
non-neuronal cells forwestern blot analysis, immunoﬂuorescence anal-
ysis allowed us to compare these two cell phenotypes with respect to
the expression of VGluT1 and ChAT. VGluT1 immunoreactivity in ﬂat
polygonal non-neuronal cells (Figs. 5B–D, stars) was mostly restricted
to perinuclear locations (Fig. 5B), whereas ChAT-staining extended fur-
ther to thewhole cytoplasm (Fig. 5C), even delineating thewhole cellu-
lar perimeter.
3.5. AraC/NT2 neurons are irreversibly postmitotic
Cell proliferation was assessed by BrdU incorporation and cell
counting during the time course AraC-induced neuronal differentiation.
About three-quarters (75.32 ± 1.32%) of NT2 progenitors incorporated
BrdU after a 4-h pulse prior to ﬁxation (Figs. 6A, F). Treatmentwith AraC
rapidly inhibited DNA replication. Thus, in NT2 cells incubated with
BrdU during the ﬁrst 4 h of AraC treatment, the proportion of BrdU-
immunopositive cells felt to less than half (48.90 ± 1.59%) (Figs. 6B,
F) and decreased steadily during the next 12 h of AraC treatment
(Figs. 6C–E, F), such that no BrdU-immunopositive cells were detected
after this time point.orescence to VGluT1 (red) and ChAT (red) combined with Hoechst's staining (blue). (A)
ctive. (B–D) Higher magniﬁcation of the area framed in A for a better view of VGluT1
in non-neuronal cells (stars). Scale bars = 100 μm in A; 50 μm in D.
Fig. 6. (A–D) Epiﬂuorescence microscopy images of NT2 cells subjected to 4-h BrdU pulses during the time course of AraC-induced differentiation and processed for double
immunoﬂuorescence against BrdU (red) and β-III tubulin (green), combined with Hoechst's chromatin staining (blue). Filled and empty arrowheads correspond to BrdU-positive and
BrdU-negative cells. Scale bar = 50 μm (applies to A–D). (G) Bar graphs showing results of BrdU incorporation analysis during the time course of AraC-induced differentiation of NT2
cells. Data represent mean ± SEM from three independent experiments.
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reversible, AraC-containing medium was replaced with fresh complete
medium after the 6-day period of treatment, and cells were subjected
to 4-h BrdU pulses before ﬁxation at different time points. Cells ﬁxed
24, 48, or 96 h after removal of AraC failed to incorporate BrdU
(Fig. S5), strongly suggesting that AraC/NT2 cells are postmitotic and
unable to return to a premitotic state. Noticeably, cell viability decreased
rapidly after removal of AraC, such that only a few cells (b100/slide)
remained viable by day 5. To rule out that failure of BrdU incorporation
after 4-h pulseswas caused by a slowdown in cell cycle progression, ad-
ditional experiments were performed in cell cultures ﬁxed at the same
time points, but exposed to BrdU during 24 h before ﬁxation. Again,
noBrdU labelingwasdetected in these conditions (Fig. S5), demonstrat-
ing that AraC/NT2 neurons are irreversibly postmitotic.
4. Discussion
NT2 derived neuronal cells in vitro express a plethora of neuron-
speciﬁc markers at both transcript and protein levels (Pleasure et al.,
1992; Cheung et al., 1999; Megiorni et al., 2005; Couillard-Despres
et al., 2008; Haile et al., 2014). Our results are roughly in line with pre-
vious studies showing increased expression of NF200 (Lee and
Andrews, 1986; Pleasure et al., 1992), β-III tubulin (Megiorni et al.,
2005; Couillard-Despres et al., 2008; Popovic et al., 2014), and DCX dur-
ing RA-induced differentiation (Couillard-Despres et al., 2008). Howev-
er, differences in culture conditions and the lack of data of the time
course expression (or election of unequal time points for analysis) in
these studies make it difﬁcult a reliable comparison between their and
our results. An inherent limitation for interpretation of results arises
from the heterogeneous composition of cultures during RA-induced dif-
ferentiation. Indeed, the neuronal phenotype represents only a small
fraction over the entire cell population before mechanical isolation of
RA/NT2N cells. Of the three markers used, NF200 was clearly identiﬁedas a highly neuron-speciﬁc marker in terminal cultures, in view of the
high enrichment in this protein in terminally differentiated RA/NT2N
cells compared to cell samples harvested before mechanical dislodging
of neuronal cells. By contrast, expression levels of β-III tubulin and
DCX were similar in samples from cultures after 28 days of treatment
and in those from terminally differentiated RA/NT2N cells, indicating
that these proteins were expressed in both RA/NT2N neurons and in
the highly adherent non-neuronal NT2A cells. Remarkably, β-III tubulin
was already detectable in NT2 cells, reached a maximum immunoreac-
tivity by day 7 of RA treatment, and returned to basal levels at the end of
the process. This is in agreementwith a similar time course analysis per-
formedbyMegiorni et al. (2005), even thought they used a cell aggrega-
tion method that shortens the time of the RA-induced differentiation to
3–4 weeks. Collectively, these data support and extend previous ﬁnd-
ings of the expression of neuronal markers in RA/NT2N neurons and
emphasizes the caution needed in drawing conclusions about the use
of β-III tubulin for an unequivocal identiﬁcation of neuronal pheno-
types. In line with this conclusion, β-III tubulin is expressed in human
fetal astrocytes (Dráberová et al., 2008) as well as in undifferentiated
mesenchymal stem cells (Foudah et al., 2014). Our ﬁndings show that
NT2N cells derived from AraC treatment not only show neuronal mor-
phology, but also express neuronal markers, albeit with remarkable dif-
ferences in the expression proﬁles of β-III tubulin and DCX during
differentiation. At difference with that observed during RA-induced dif-
ferentiation, in AraC-treated cultures, immunoreactivity forβ-III tubulin
increased sharply at mid-treatment and reached a maximum at day 6,
whereas DCX showed an up-down regulation pattern that peaked up
at 48 h post-treatment. The progressive increase in expression of
NeuN/Fox-3 observed during AraC-induced differentiation of NT2 pro-
genitors, as analyzed by western blot and immunoﬂuorescence micros-
copy, further conﬁrmed the neuronal identity of AraC/NT2N neurons.
The sequential and non-matching upregulation of the early (Brown
et al., 2003) and late (Mullen et al., 1992) neuronal markers DCX and
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begun a maturation process after 6 days of treatment. However, this
suggestion should be considered with caution, as NeuN/Fox-3 expres-
sion has been found in non-neuronal cells, such as cultured rodent
and human astrocytes and even 3T3 ﬁbroblast cells (Darlington et al.,
2008). Indeed, we also observed that part of the population of non-
neuronal ﬂat polygonal cells in our AraC-treated terminal cultures
displayed weak to moderate nuclear staining for NeuN/Fox-3, leading
us to consider morphological features to classify cells into non-
neuronal or AraC/NT2N neuronal. Less than 10% of the cells in culture
survived the uninterrupted 6-day period of AraC treatment, and only
about 50% of them fulﬁlled the double criterion to be considered as neu-
ronal (i.e., NeuN/Fox-3 positive nucleus and presence of neurite exten-
sions) leading to a differentiation efﬁciency similar to that found after
RA-differentiation. Our modiﬁed procedure, consisting of increasing
cell density at mid-treatment, doubled overall cell survival and in-
creased the percentage of neuronal cells with respect the total popula-
tion at the end of AraC treatment to 71%, respectively. Consequently,
differentiation efﬁciency was number augmented by almost 3-fold.
The two populations identiﬁed were clearly distinguishable as dem-
onstrated by morphometric measurements of cell nuclei and total cell
area. When compared with RA/NT2N neurons, AraC/NT2N neurons
displayed considerably larger nuclei and cell somata, although the
ratio of nuclear area to body area tended to get closer in both pheno-
types, but still signiﬁcantly lower in AraC/NT2N neurons. An overesti-
mation of the size of cell somata of AraC/NT2N neurons, due to
limitations on accurately deﬁning their boundaries of (González-
Burguera et al., in press), could account for this difference. Morphomet-
ric analysis of neurites showed that AraC/NT2N neurons displayed an
average neurite length of about 105 μm, which corresponds to less
than half the length of 225 μm observed in RA/NT2 neurons. This
value is consistent with data by Haile et al. (2014), which reported an
average neurite length of about 240 μm in RA/NT2N neurons. However,
because the average number of RA/NT2N neurites reported by Haile
et al. (2014) was about 1.5-fold higher, the total neurite length per
cell (about 759 μm) observed by these authors was almost double as
comparedwith our data (about 390 μm). Eitherway, ourmeasurements
show a 2.2-fold greater total arborization length for RA/NT2N than for
AraC/NT2N neurons. The much shorter time period for neurite out-
growth in AraC/NT2N neurons likely accounts for this difference. In-
deed, AraC/NT2N neurons were enriched in lamellar extensions and
ﬁlopodia-like processes, indicative of intensive neurite outgrowth
activity. In support of this idea, neurite length found here was
about 20% longer than that reported by Tegenge et al. (2011) in
RA-differentiated neurons using the shortened cell aggregation
method described by Cheung et al. (1999). Hence, longer survival pe-
riods would be probably required for AraC-differentiated neurons to
develop longer neurite arborizations. However, under the present
culture conditions, the reduction in cell viability observed after the
end of the 6-day period of AraC treatment did not allow such a
long-term analysis. Therefore, increasing stability of AraC/NT2 neu-
rons by testing different culture conditions (includingmedia, growth
factors, matrices, and/or co-culture with astrocytes) will be one of
the major challenges for future. Whatever the case, the experimental
results reported here reveal that NT2 progenitors can be committed
to differentiate in a short time period and with high efﬁciency into
postmitotic neurons (as demonstrated by BrdU incorporation as-
says), and underline that AraC-induced differentiation of NT2 cells
represents a valuable model to study molecular mechanisms under-
lying neuronal differentiation.
RA/NT2N neurons have been shown to express a broad spectrum of
neurotransmitter markers in vitro, including glutamatergic (Podrygajlo
et al., 2009; Coyle et al., 2011), cholinergic (Guillemain et al., 2000;
Saporta et al., 2000), GABAergic (Yoshioka et al., 1997; Guillemain et al.,
2000; Saporta et al., 2000; Podrygajlo et al., 2009; Coyle et al., 2011), cat-
echolaminergic (Guillemain et al., 2000; Saporta et al., 2000), andserotonergic (Podrygajlo et al., 2009) transcripts and/or proteins. The ap-
parent absence of consensus on the ﬁnal neurotransmitter phenotype can
be attributed to differences in the neuronal differentiation protocol and
culture conditions, although as discussed by Podrygajlo et al. (2009), pas-
sage number of precursors, or their genetic instability could also contrib-
ute to variability of results. Nevertheless, under the culture conditions
(culture media included) described by Pleasure et al. (1992) and used
here, Yoshioka et al. (1997) and Guillemain et al. (2000) reported that a
considerable population of neurons possess a GABAergic phenotype, in
agreementwith our ﬁndings showing that RA/NT2 aremostly GABAergic.
In their immunocytochemistry-based study, Guillemain et al. (2000)
found that 66.5% of neurons were GABA-immunopositive, although they
also reported that 51.8% and 49.5% of neurons were TH- and ChAT-
immunoreactive, respectively, leading to the conclusion that many neu-
rons were immunopositive for at least two markers. For their part,
Yoshioka et al. (1997) only analyzed GAD67 transcript and protein
using RT-PCR andwestern blot analysis. Here, using immunoﬂuorescence
microscopy, we observed a large amount of GAD67-immunopositive and
scarce VGluT1-immunopositive thin neurites, both likely corresponding
to axons; hence, to the canonical distribution of these proteins. Although,
due to this distribution pattern, we could not asses the proportion of neu-
rons of each phenotype, western blot analysis conﬁrmed that, in our cul-
ture conditions, GABA is the major neurotransmitter in RA/NT2N cells,
whereas only a weak VGluT1 signal could be observed.
Of particular interest in the present report is the ﬁnding that cells
committed to differentiate by short treatment with AraC displayed a
completely different neurotransmitter phenotype when compared
with RA/NT2N neurons. Western blot analysis showed strong immu-
noreactivity for VGluT1 and ChAT in samples from terminal cultures,
starting as soon as 72 h after initiation of AraC treatment. On the
other hand, immunoﬂuorescence assays evidenced that virtually all
terminally differentiated neurons co-expressed both markers, sug-
gesting that their neurotransmitter phenotype was not fully deﬁned.
Noticeably, this same phenomenon has been recently described for
hippocampal embryonic neural progenitors. Thus, Bhargava et al.
(2010) reported that when cultures were obtained from brain of
18 days old embryos, most VGluT1-positive neurons also expressed
ChAT protein. On the contrary, this ability to co-express both
markers of neurotransmitter phenotype was not observed in cul-
tures from either neonatal or adult hippocampus. Results by
Bhargava et al. (2010) exemplify the importance of tissue environ-
mental signals in speciﬁcation of neurotransmitter fate. Moreover,
embryonic hippocampal neurons in culture express the late neuro-
nal marker NeuN/Fox-3 (Taguchi et al., 2014), indicating that neuro-
nal maturation and speciﬁcation of neurotransmitter phenotype are
separate developmental events. As discussed by Bhargava et al.
(2010), a complex combinational strategy of electrochemical coding
that involves neighboring environmental signals, as well as distant
afferent and retrograde signals, appear to account for speciﬁcation
of neurotransmitter phenotype (Johnson, 1994; Asmus et al., 2000;
Landis, 2002). As a result of this developmental process, neurons
would loss the ability to synthesize multiple neurotransmitters. In
this regard, it is likely that AraC/NT2N cells could acquire a speciﬁc
neurotransmitter phenotype when engrafted in brain. In support of
this, previous studies have demonstrated that RA/NT2N neurons
(Saporta et al., 2000) and even NT2 progenitors (Miyazono et al.,
1996) transplanted in different regions of the rodent brain are driven
to differentiate in speciﬁc neurotransmitter phenotypes according to
local environmental cues. Although some experimental studies using
RA/NT2N grafts in animal models of stroke (Borlongan et al., 1998a,
1998b; Saporta et al., 1999) and Huntington's disease (Hurlbert
et al., 1999) have yielded promising results, others have reported ei-
ther limited improvement (Bliss et al., 2006), or no effects on behav-
ior or neurological function (Baker et al., 2000; Zhang et al., 2005;
Bliss et al., 2006), which has been attributed, at least in part, to the
low amount of neurons of the desired neurotransmitter phenotype,
550 I. González-Burguera et al. / Stem Cell Research 16 (2016) 541–551which is a key prerequisite for successful neuronal replacement. Fu-
ture studies will disclose whether AraC/NT2N cells are a suitable
source of glutamatergic and cholinergic neurons for replacement of
cortical excitatory neurons and basal forebrain cholinergic neurons
in animal models of ischemic insult and Alzheimer's disease.
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